Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/5/2017
SIETES contiene 91791 citas

 
 
 1 a 20 de 842 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. WHO’s travel expenses exceed what it spends on some diseases. DIA Daily 2017:1. [Ref.ID 101587]
2. Cita con resumen
Pease AM, Krumholz HM, Hines HH, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680. [Ref.ID 101573]
4. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
5. Cita con resumen
6. Cita con resumen
Chanq Z, Quinn PD, Hur K, Gibbons RD, Sjolander A, Larsson H, D'Onofrio BM. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 2017:10 de mayo. [Ref.ID 101569]
7. Cita con resumen
Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 2017;317:1854-63. [Ref.ID 101567]
9. Cita con resumen
Mudd PA, Thottathil P, Giordano T, Wetmore RF, Elden L, Jawad AF, Ahumada L, Gálvez JA. Association between ibuprofen use and severity of surgically managed posttonsillectomy hemorrhage. JAMA Otolaryngol Head Neck Surg 2017:4 de mayo. [Ref.ID 101564]
10. Cita con resumen
11. Cita con resumen
Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, Wu T, Schoen-baum M, Hutchins D, Brennan T, Loewen-stein G. Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 2017;317:1785-95. [Ref.ID 101559]
12.Enlace a cita original Cita con resumen
Anónimo. Flutamida: casos graves de hepatotoxicidad asociados al uso fuera de las condiciones autorizadas. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:27 de abril. [Ref.ID 101552]
15. Cita con resumen
Schick A, Miller KL, Lanthier M, Pan GD, Nardinelli C. Evaluation of pre-marketing factors to predict post-marketing boxed warnings and safety withdrawals. Drug Saf 2017:24 de marzo. [Ref.ID 101505]
16. Cita con resumen
Prada-Ramallal G, Takkouche B, Figueiras A. Diverging conclusions from the same meta-analysis in drug safety: source of data (primary versus secondary) takes a toll. Drug Saf 2017;40:351-8. [Ref.ID 101501]
17. Cita con resumen
Anónimo. Litigation is new tactic in opioid crisis. DIA Daily 2017:1. [Ref.ID 101500]
19. Cita con resumen
Anónimo. MSF, Medecins du Monde challenge Gilead’s sofosbuvir patent. DIA Daily 2017:1. [Ref.ID 101490]
Seleccionar todas
 
 1 a 20 de 842 siguiente >>